Nectar Lifesciences Limited (NSE:NECLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 8.02B |
| Revenue (ttm) | 16.81B |
| Net Income (ttm) | 170.01M |
| Shares Out | 224.26M |
| EPS (ttm) | 0.74 |
| PE Ratio | 48.08 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 651,658 |
| Average Volume | 793,132 |
| Open | 38.50 |
| Previous Close | 37.94 |
| Day's Range | 35.00 - 38.90 |
| 52-Week Range | 26.15 - 56.50 |
| Beta | 1.13 |
| RSI | 52.96 |
| Earnings Date | Feb 11, 2025 |
About Nectar Lifesciences
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablet... [Read more]
Financial Performance
Financial StatementsNews
Nectar Lifesciences shares surge nearly 5% as Q3 profit jumps 400% YoY
Shares of Nectar Lifesciences Limited rose by 4.98% to ₹35.60 on Thursday following the company’s stellar financial performance for Q3 FY25. The company posted a 400% year-on-year (YoY) increase in pr...
Nectar Lifesciences Q3 FY25 results: Profit after tax rises nearly 400% YoY to Rs 7.84 crore
Nectar Lifesciences Limited has delivered robust financial performance for the quarter ended December 31, 2024 (Q3 FY25), driven by improved margins, strong operational efficiencies, and strategic mar...